STOCK TITAN

CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

CNS Pharmaceuticals (NASDAQ:CNSP) reported a narrower third-quarter 2026 net loss while advancing discussions to acquire or license therapeutic assets. Net loss was approximately $2.5 million, or $0.24 per basic and diluted share, versus approximately $3.2 million, or $5.76 per share, a year earlier. Research and development expenses fell to approximately $0.9 million from $2.2 million, reflecting lower Berubicin clinical costs and TPI 287 manufacturing costs. General and administrative expenses rose to approximately $1.8 million from $1.1 million.

Cash was approximately $17.2 million at September 30, 2026, versus $7.2 million at December 31, 2025, primarily reflecting the May 2026 private placement. The company expects funding beyond the next twelve months and targets its first pipeline-building transaction by year-end 2026. Discussions concern neurology, oncology or rare-disease assets; no completed transaction was announced.

Loading...
Loading translation...
5 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointCash increased to approximately $17.2 million at September 30, 2026, from approximately $7.2 million at December 31, 2025.
  • Moderate pointThird-quarter net loss narrowed to approximately $2.5 million, or $0.24 per share, versus approximately $3.2 million, or $5.76, in 2025.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.CNS believes cash resources can fund planned operations beyond the next twelve months.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.CNS targets its first acquisition or licensing transaction for pipeline expansion by year-end 2026.
  • Minor pointThird-quarter research and development expenses fell to approximately $0.9 million, from approximately $2.2 million in 2025.

Negative

  • Moderate pointPipeline asset acquisitions or licenses remain in advanced discussions with potential counterparties.
  • Minor pointThird-quarter general and administrative expenses rose to approximately $1.8 million, from approximately $1.1 million in 2025.

Key Figures

Research and development expenses: approximately $0.9 million vs. approximately $2.2 million General and administrative expenses: approximately $1.8 million vs. approximately $1.1 million Net loss: approximately $2.5 million vs. approximately $3.2 million +5 more
Research and development expenses
approximately $0.9 million vs. approximately $2.2 million
Third quarter 2026 vs. the same period in 2025
General and administrative expenses
approximately $1.8 million vs. approximately $1.1 million
Third quarter 2026 vs. the same period in 2025
Net loss
approximately $2.5 million vs. approximately $3.2 million
Third quarter 2026 vs. third quarter 2025
Net loss per share
approximately $0.24 vs. $5.76 per basic and diluted share
Third quarter 2026 vs. third quarter 2025
Cash and cash equivalents
approximately $17.2 million vs. approximately $7.2 million
As of September 30, 2026 vs. December 31, 2025
Private placement financing
$22.5 million
Previously announced financing completed in May 2026; net proceeds contributed to the cash increase
Planned operations funding
beyond the next twelve months
Company believes cash resources are sufficient to fund planned operations
First pipeline-building transaction target
by year-end 2026
Company’s stated strategic milestone

Previous Earnings Reports

2 past events · Latest: Aug 12
Same Type 2 events
  1. Aug 12

    Quarterly earnings

    24h Move
    -8.9%

    Reported a strengthened cash position while pursuing asset acquisitions and licensing.

  2. Nov 17

    Quarterly earnings

    24h Move
    -2.9%

    Reported lower year-over-year net loss, cash runway, and Phase 1 TPI 287 responses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement
1 terms
private placement financial
"net proceeds from the Company's previously announced $22.5 million private placement financing"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

HOUSTON, TX / ACCESS Newswire / November 16, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2026 and provided an update on its corporate strategy.

CNS Pharmaceuticals continues to make meaningful progress in executing its pipeline expansion strategy, advancing discussions with potential counterparties regarding the acquisition or licensing of innovative therapeutic assets in neurology, oncology or rare disease. The Company remains focused on completing its first pipeline-building transaction by year-end 2026, an important anticipated milestone in its strategic transformation.

"We are approaching an important inflection point in the evolution of CNS Pharmaceuticals," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "Our efforts to identify and evaluate compelling therapeutic opportunities have progressed into advanced discussions with potential counterparties, bringing us closer to establishing the foundation of our next-generation pipeline. We are encouraged by the quality of the opportunities under consideration and remain intensely focused on translating these discussions into a meaningful transaction. Our objective is clear: secure a differentiated asset with the potential to drive clinical development, establish a platform for future growth and create long-term shareholder value. We look forward to delivering on this important strategic priority."

Third Quarter 2026 Financial Results

Research and development expenses were approximately $0.9 million for the third quarter of 2026, compared to approximately $2.2 million for the same period in 2025. The decrease was primarily attributable to lower clinical costs related to Berubicin following the completion of enrollment and patient treatments in its clinical trial, as well as lower TPI 287 manufacturing costs. These decreases were partially offset by increased personnel-related expenses. Future research and development expenses will depend on the timing and nature of any assets the Company in-licenses or acquires and the associated development activities.

General and administrative expenses were approximately $1.8 million for the third quarter of 2026, compared to approximately $1.1 million for the same period in 2025. The increase was primarily attributable to higher consulting expenses, mainly related to business development, and increased personnel-related expenses, partially offset by lower professional services expenses.

Net loss for the third quarter of 2026 was approximately $2.5 million, or $0.24 per basic and diluted share, compared to a net loss of approximately $3.2 million, or $5.76 per basic and diluted share, for the third quarter of 2025.

Cash and cash equivalents were approximately $17.2 million as of September 30, 2026, compared to approximately $7.2 million as of December 31, 2025. The increase primarily reflects net proceeds from the Company's previously announced $22.5 million private placement financing completed in May 2026. The Company believes that its cash resources, including the net proceeds from the May 2026 financing, are sufficient to fund its planned operations beyond the next twelve months.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the Company's ability to identify, acquire and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and the timing related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risk that current discussions may not result in a definitive transaction, that any acquired or licensed asset may not achieve clinical or commercial success, that additional capital may be required to fund future operations or transactions, as well as market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

Business Development Contact
CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.com

SOURCE: CNS Pharmaceuticals, Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were CNS Pharmaceuticals' third-quarter 2026 financial results?

CNS Pharmaceuticals reported a net loss of approximately $2.5 million, or $0.24 per basic and diluted share, compared with approximately $3.2 million, or $5.76 per basic and diluted share, in the third quarter of 2025. Research and development expenses decreased, while general and administrative expenses increased.

When does CNS Pharmaceuticals aim to complete its first pipeline-building transaction?

CNS Pharmaceuticals targets completion of its first pipeline-building transaction by year-end 2026. It is in advanced discussions with potential counterparties about acquiring or licensing therapeutic assets in neurology, oncology or rare disease.

Why did CNS Pharmaceuticals' general and administrative expenses rise in the third quarter of 2026?

The increase primarily reflected higher consulting expenses, mainly for business development, and increased personnel-related expenses. Lower professional services expenses partially offset those increases.

What drove CNS Pharmaceuticals' cash increase through September 2026?

The cash increase primarily reflected net proceeds from the $22.5 million private placement financing completed in May 2026. Cash and cash equivalents were approximately $17.2 million at September 30, 2026, compared with approximately $7.2 million at December 31, 2025.

Keep reading